This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.

中文翻译：

---

重新审视美国-墨西哥-加拿大协定对公共健康的影响。

该评论重新审视了Labonté等人的最新文章，该文章最近对《美国-墨西哥-加拿大协定》（USMCA）最终版本中与专利权有关的两项相关规定进行了更改。尽管USMCA的最终修订版没有比三个贸易伙伴中已有的专利保护增加更多的药品专利保护，但是该协议在增加仿制药和生物仿制药的获取方面没有做任何事情。